West Family Investments Inc. Has $513,000 Stake in Regeneron Pharmaceuticals, Inc. $REGN

West Family Investments Inc. lowered its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 14.1% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 977 shares of the biopharmaceutical company’s stock after selling 160 shares during the period. West Family Investments Inc.’s holdings in Regeneron Pharmaceuticals were worth $513,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Activest Wealth Management boosted its position in shares of Regeneron Pharmaceuticals by 110.5% in the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 21 shares during the period. Costello Asset Management INC acquired a new stake in shares of Regeneron Pharmaceuticals in the first quarter valued at approximately $27,000. Saudi Central Bank acquired a new stake in shares of Regeneron Pharmaceuticals in the first quarter valued at approximately $27,000. Migdal Insurance & Financial Holdings Ltd. acquired a new position in Regeneron Pharmaceuticals in the 2nd quarter valued at $31,000. Finally, Colonial Trust Advisors bought a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter valued at $32,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, VP Jason Pitofsky sold 431 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, November 7th. The shares were sold at an average price of $651.43, for a total transaction of $280,766.33. Following the transaction, the vice president owned 4,233 shares in the company, valued at approximately $2,757,503.19. The trade was a 9.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Christine A. Poon sold 6,500 shares of the firm’s stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total value of $4,252,755.00. Following the transaction, the director directly owned 2,352 shares of the company’s stock, valued at approximately $1,538,843.04. This represents a 73.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 7.02% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Stock Down 0.7%

Shares of NASDAQ:REGN opened at $779.09 on Friday. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $800.99. The company has a market capitalization of $81.88 billion, a PE ratio of 18.66, a price-to-earnings-growth ratio of 2.03 and a beta of 0.31. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.06. The company has a fifty day moving average of $634.75 and a 200-day moving average of $583.49.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, topping analysts’ consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The business had revenue of $3.75 billion for the quarter, compared to analyst estimates of $3.57 billion. During the same quarter in the previous year, the company posted $12.46 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up .9% compared to the same quarter last year. On average, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 5th. Stockholders of record on Thursday, November 20th will be paid a $0.88 dividend. The ex-dividend date of this dividend is Thursday, November 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.43%.

Analyst Ratings Changes

A number of brokerages recently commented on REGN. Guggenheim raised their price target on Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Royal Bank Of Canada raised their target price on shares of Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the company a “sector perform” rating in a report on Wednesday, October 29th. HSBC began coverage on shares of Regeneron Pharmaceuticals in a research report on Monday, November 24th. They issued a “buy” rating and a $255.00 target price for the company. Morgan Stanley reduced their price target on shares of Regeneron Pharmaceuticals from $761.00 to $756.00 and set an “overweight” rating on the stock in a research report on Friday, October 10th. Finally, Hsbc Global Res upgraded shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a research report on Monday, November 24th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $757.91.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.